Pranlukast, a cysteinyl leukotriene antagonist, reduces serum eosinophil cationic protein levels in patients with asthma

Hiroshima Journal of Medical Sciences

Volumn 48, Issue 4, 1999, Pages 105-110

  Ishioka, Shinichi ^a   Hozawa, Soichiro ^a   Haruta, Yoshinori ^a   Hiyama, Keiko ^a   Maeda, Akihiro ^a   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Bronchial asthma; Cysteinyl leukotriene receptor antagonist; Pranlukast; Serum eosinophil cationic protein

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE; PRANLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHRONIC INFLAMMATION; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; EOSINOPHIL; FEMALE; HUMAN; MALE; PEAK EXPIRATORY FLOW; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BLOOD PROTEINS; CHROMONES; EOSINOPHIL GRANULE PROTEINS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; RIBONUCLEASES;

EID: 0033510887     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Adelroth, E., Morris, M.M., Hargreave, F.E. and O'Byrne, P.M. 1986. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N. Engl. J. Med. 315: 480-484.
2. Adelroth, E., Rosenhall, L., Johansson, S.A., Linden, M. and Venge, P. 1990. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. Am. Rev. Respir. Dis. 142: 91-99.
3. Ahlstedt, S. 1995. Clinical application of eosinophilic cationic protein in asthma. Allergy Proc. 16: 59-62.
4. Barnes, N.C., Piper, P.J. and Costello, J.F. 1984. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 39: 500-504.
5. Barnes, N.C. and Pujet, J.C. 1997. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 52: 523-527.
6. Borgeat, P. and Samuelsson, B. 1979. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J. Biol. Chem. 254: 2643-2646.
7. Bousquet, J., Chanez, P., Lacoste, J.Y., Barneon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony Lafontaine, J., Godard, P. and Michel, F.B. 1990. Eosinophilic inflammation in asthma. N. Engl. J. Med. 323: 1033-1039.
8. Dahlen, S.E., Hedqvist, P., Hammarstrom, S. and Samuelsson, B. 1980. Leukotrienes are potent constrictors of human bronchi. Nature 288: 484-486.
9. Diamant, Z., Hiltermann, J.T., van, R.E., Callenbach, P.M., Veselic, C.M., van, d. Veen. H., Sont, J.K. and Sterk, P.J. 1997. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am. J. Respir. Crit. Care Med. 155: 1247-1253.
10. Djukanovic, R., Roche, W.R., Wilson, J.W., Beasley, C.R., Twentyman, O.P., Howarth, R.H. and Holgate, S.T. 1990. Mucosal inflammation in asthma. Am. Rev. Respir. Dis. 142: 434-457.
11. Drazen, J.M. and Austen, K.F. 1987. Leukotrienes and airway responses. Am. Rev. Respir. Dis. 136: 985-998.
12. Frigas, E., Motojima, S. and Gleich, G.J. 1991. The eosinophilic injury to the mucosa of the airways in the pathogenesis of bronchial asthma. Eur. Respir. J. Suppl. 13: 123s-135s.
13. Grossman, J., Faiferman, I., Dubb, J.W., Tompson, D.J., Busse, W., Bronsky, E., Montanaro, A., Southern, L. and Tinkelman, D. 1997. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J. Asthma 34: 321-328.
14. Hamilton, A., Faiferman, I., Stober, P., Watson, R.M. and O'Byrne, P.M. 1998. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early-and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J. Allergy Clin. Immunol. 102: 177-183.
15. Kaye, M.G. and Smith, L.J. 1990. Effects of inhaled leukotriene D4 and platelet-activating factor on airway reactivity in normal subjects. Am. Rev. Respir. Dis. 141: 993-997.
16. Laitinen, L.A., Laitinen, A., Haahtela, T., Vilkka, V., Spur, B.W. and Lee, T.H. 1993. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341: 989-990.
17. Lewis, R.A., Austen, K.F. and Soberman, R.J. 1990. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323: 645-655.
18. Manning, P.J., Rokach, J., Malo, J.L., Ethier, D., Cartier, A., Girard, Y., Charleson, S. and O'Byrne, P.M. 1990. Urinary leukotriene E4 levels during early and late asthmatic responses. J. Allergy Clin. Immunol. 86: 211-220.
19. Marom, Z., Shelhamer, J.H., Bach, M.K., Morton, D.R. and Kaliner, M. 1982. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am. Rev. Respir. Dis. 126: 449-451.
20. National Institutes of Health, National Heart, Lung and Blood Institute. 1995. Global Initiative for Asthma (Global strategy for asthma management and prevention. NHLBI/WHO workshop report). 95: 3659.
21. Niimi, A., Amitani, R., Suzuki, K., Tanaka, E., Murayama, T. and Kuze, F. 1998. Serum eosinophil cationic protein as a marker of eosinophilic inflammation in asthma. Clin. Exp. Allergy 28: 233-240.
22. O'Hickey, S.P., Hawksworth, R.J., Fong, C.Y., Arm, J.P., Spur, B.W. and Lee, T.H. 1991. Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways. Am. Rev. Respir. Dis. 144: 1053-1057.
23. O'Shaughnessy, T.C., Georgiou, P., Howland, K., Dennis, M., Compton, C.H. and Barnes, N.C. 1997. Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers. Thorax 52: 519-522.
24. Obata, T., Katsube, N., Miyamoto, T., Toda, M., Okegawa, T., Nakai, H., Kosuge, S., Konno, M., Arai, Y. and Kawasaki, A. 1985. New antagonists of leukotrienes: ONO-RS-411 and ONO-RS-347. Adv. Prostaglandin Thromboxane Leukot. Res. 15: 229-231.
25. Okubo, T., Takahashi, H., Sumitomo, M., Shindoh, K. and Suzuki, S. 1987. Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients. Int. Arch. Allergy Appl. Immunol. 84: 149-155.
26. Reiss, T.F., Altman, L.C., Chervinsky, P., Bewtra, A., Stricker, W.E., Noonan, G.P., Kundu, S. and Zhang, J. 1996. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J. Allergy Clin. Immunol. 98: 528-534.
27. Samuelsson, B., Dahlen, S.E., Lindgren, J.A., Rouzer, C.A. and Serhan, C.N. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237: 1171-1176.
28. Spector, S.L., Smith, L.J. and Glass, M. 1994. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care Med. 150: 618-623.
29. Sur, S., Adolphson, C.R. and Gleich, G.J. 1993. Eosinophil, Biochemical and cellular aspects, p. 169-200, In Mosby-Year Book, St. Louis.
30. Tamaoki, J., Kondo, M., Sakai, N., Nakata, J., Takemura, H., Nagai, A., Takizawa, T. and Konno, K. 1997. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 155: 1235-1240.
31. Taniguchi, Y., Tamura, G., Honma, M., Aizawa, T., Maruyama, N., Shirato, K. and Takishima, T. 1993. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J. Allergy Clin. Immunol. 92: 507-512.
32. Taylor, G.W., Taylor, I., Black, P., Maltby, N.H., Turner, N., Fuller, R.W. and Dollery, C.T. 1989. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1: 584-588.
33. Taylor, I.K., O'Shaughnessy, K.M., Fuller, R.W. and Dollery, C.T. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337: 690-694.
34. U.S. Department of Health and Human Services, Public Health Service, National Institute of Health. 1992. International consensus report on diagnosis and management of asthma.
35. Underwood, D.C., Osborn, R.R., Newsholme, S.J., Torphy, T.J. and Hay, D.W. 1996. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am. J. Respir. Crit. Care Med. 154: 850-857.
36. Venge, P. 1993. Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma. Clin. Exp. Allergy 2: 3-7.
37. Wardlaw, A.J., Hay, H., Cromwell, O., Collins, J.V. and Kay, A.B. 1989. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J. Allergy Clin. Immunol. 84: 19-26.
38. Wenzel, S.E., Larsen, G.L., Johnston, K., Voelkel, N.F. and Westcott, J.Y. 1990. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. 142: 112-119.
39. Woodward, D.F., Weichman, B.M., Gill, C.A. and Wasserman, M.A. 1983. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 25: 131-142.
40. Yamaguchi, T., Kohrogi, H., Honda, I., Kawano, O., Sugimoto, M., Araki, S. and Ando, M. 1992. A novel leukotriene antagonist, ONO-1078, inhibits and reverses human bronchial contraction induced by leukotrienes C4 and D4 and antigen in vitro. Am. Rev. Respir. Dis. 146: 923-929.